<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="322">
  <stage>Registered</stage>
  <submitdate>31/10/2002</submitdate>
  <approvaldate>31/10/2002</approvaldate>
  <nctid>NCT00048425</nctid>
  <trial_identification>
    <studytitle>Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.</studytitle>
    <scientifictitle>Randomized, Multicenter Evaluation of Intravenous Levosimendan Efficacy Versus Placebo in the Short Term Treatment of Decompensated Chronic Heart Failure: the REVIVE II Study.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>3001069</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure, Congestive</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Levosimendan

Treatment: drugs: Levosimendan


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A clinical composite classification incorporating a Patient Global Assessment at 6 hours, 24 hours and Day 5, combined with clinical criteria for worsening heart failure through 5 days after the start of the study drug infusion.</outcome>
      <timepoint />
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A written informed consent must be obtained for hospitalized male or female patients
             over 18 years old of age.

          -  The eligible patients must be diagnosed with worsening heart failure as evidenced by
             dyspnea at rest, poor ejection fraction and have been treated with IV diuretics.

          -  It is allowable for the patients to be treated with IV inotropes and vasodilators.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>The following criteria would exclude the patient from study:

          -  invasive cardiac procedure (e.g. cardiac surgery, LVAD, cardioversion, cardiac
             re-synchronization),

          -  rhythm disorders (e.g. earlier Torsades de Pointes, increased heart rate),

          -  severe ventricular outflow obstruction,

          -  angina,

          -  hypotension,

          -  uncorrected hypokalemia,

          -  CNS (e.g. stroke, TIA),

          -  respiratory (e.g. COPD, intubated patients, oral,

          -  intravenous or intramuscular steroids),

          -  renal insufficiency (e.g. increased serum creatinine, dialysis),

          -  hepatic impairment (e.g. significant increase in liver enzymes),

          -  decompensation from active infection and acute bleeding (e.g. severe anemia).

          -  Female patients of child bearing potential must have a negative pregnancy test and use
             adequate contraceptive precautions.

          -  Also excluded is the use of amrinone and milrinone prior to randomization, a history
             of hypersensitivity to levosimendan or any of the excipients and previous
             participation in a clinical trial with any experimental treatment within the last 30
             days.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2002</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Canberra Hospital/Cardiology Department - Garran</hospital>
    <hospital>Royal Prince Alfred Hospital/Department of Cardiology - Camperdown</hospital>
    <hospital>Concord Hospital - Heart Failure Clinic/Department of Cardiology - Concord</hospital>
    <hospital>Gosford Hospital - Gosford</hospital>
    <hospital>Liverpool Hospital - Cardiology Research - Liverpool</hospital>
    <hospital>Prince of Wales Hospital - Randwick</hospital>
    <hospital>Royal North Shore Hospital - Cardiology Department - St. Leonards</hospital>
    <hospital>St. George Hospital/Cardiology Department - Sydney</hospital>
    <hospital>Royal Brisbane Hospital - Cardiology Department - Herston</hospital>
    <hospital>The Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>Flinders Medical Centre - Cardiac Research Department - Bedford Park</hospital>
    <hospital>Queen Elizabeth Hospital/Cardiology Department - Woodville</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Launceston General Hospital/Cardiac Research Unit - Launceston</hospital>
    <hospital>Box Hill Hospital - Coronary Care Unit - Box Hill</hospital>
    <hospital>St. Vincent's Hospital - Cardiology Investigational Unit - Fitzroy</hospital>
    <hospital>Karinia House/Geelong Hospital - Geelong</hospital>
    <hospital>Level 2, Cardiology Department/Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Heart Research Institute/Sir Charles Gairdner Hospital - Nedlands</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2050 - Camperdown</postcode>
    <postcode>NSW 2139 - Concord</postcode>
    <postcode> - Gosford</postcode>
    <postcode>2116 - Liverpool</postcode>
    <postcode> - Randwick</postcode>
    <postcode> - St. Leonards</postcode>
    <postcode> - Sydney</postcode>
    <postcode>QLD 4029 - Herston</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Fitzroy</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Montana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Ashkelon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Hadera</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Holon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Jerusalem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Nazareth</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zefat</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Zrifin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Abbott</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Orion Corporation, Orion Pharma</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the efficacy of a 24-hour infusion of levosimendan
      compared with placebo in the treatment of decompensated chronic heart failure.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00048425</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Scott Krause</name>
      <address>Abbott</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>